Main findings in four prostate cancer patients who after radical prostatectomy (RP) with (N = 1) or without (N = 3) radiotherapy showed BCR treated with a novel schedule of IS‐IIT alternated with ADT; so far, none of them has progressed to clinically overt metastatic disease. This evidence concerns the gene BCR and metastatic neoplasm.